Research2Guidance March 24, 2025
Ralf-Gordon Jahns

In an exclusive interview, founder Renato Romani from EW2Health shared how they transformed their business model to better serve the evolving needs of obesity care.

The company originally focused on stress-free weight monitoring using a Predictive Behavioral Algorithm (PBA) to help users track weight trends without daily weigh-ins. Recognizing the rise of GLP-1 medications like Ozempic and Wegovy, they pivoted to become a companion solution for clinics, offering AI-driven weight loss tracking to improve patient retention and medication efficacy. Their B2B SaaS model provides clinics with a real-time monitoring dashboard, integrating with wearables and pharmacy systems. This shift has driven rapid adoption, particularly in the Netherlands and Brazil, with plans for global expansion.

Here is how EW2Health transformed their business...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Interview / Q&A, Pharma / Biotech, Trends
Novo Nordisk Bets $200M on Triple-Targeting Drug for Obesity and Other Metabolic Diseases
Accelerate oncology drug development: A data-driven approach to clinical decisions
23andMe files for bankruptcy protection
Novo Nordisk to pay up to $2B for experimental weight loss drug
23andMe files for bankruptcy, Anne Wojcicki steps down as CEO

Share This Article